Celator(R) Pharmaceuticals Announces Positive Data and Safety Monitoring Board Recommendation for CPX-351 Phase 3 Study
December 12, 2013The Phase 3 comparing CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line therapy in older patients with high-risk acute myeloid leukemia should continue as planned without any modifications.
More »
Regado Biosciences Strengthens Executive Leadership
December 9, 2013Michael A. Metzger now serves as president and COO and oversees corporate and business development strategy and planning, as well as other key business functions of the company. Mr. Metzger was previously EVP and COO at Mersana Therapeutics.
More »
Xagenic Inc. Completes $20 Million Series B Financing
December 2, 2013Xagenic is a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result. Funding will support product development, FDA submission of testing platform and first diagnostic assay.
More »